The Biomarker Landscape in Mycosis Fungoides and Sézary Syndrome

Overview

Journal Exp Dermatol

Specialty Dermatology

Date 2016 Nov 30

PMID 27897325

Citations 18

Authors

Brittany Dulmage

Larisa Geskin

Joan Guitart

Oleg E Akilov

Affiliations

Soon will be listed here.

Abstract

The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.

Citing Articles

Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature.

Srinivas N, Peiffer L, Horny K, Lei K, Buus T, Kubat L Front Oncol. 2024; 14:1408614.

PMID: 39169943 PMC: 11337020. DOI: 10.3389/fonc.2024.1408614.

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma.

Seretis K, Sfaelos K, Boptsi E, Gaitanis G, Bassukas I Cancers (Basel). 2024; 16(5).

PMID: 38473401 PMC: 10931327. DOI: 10.3390/cancers16051044.

ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma.

Cao M, Lai P, Liu X, Liu F, Qin Y, Tu P Front Immunol. 2024; 14:1282996.

PMID: 38223508 PMC: 10786347. DOI: 10.3389/fimmu.2023.1282996.

What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?.

Akilov O Cells. 2023; 12(18).

PMID: 37759543 PMC: 10527589. DOI: 10.3390/cells12182321.

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.

Watanabe K, Gomez A, Kuramitsu S, Siurala M, Da T, Agarwal S Blood Adv. 2023; 7(14):3416-3430.

PMID: 37058474 PMC: 10345856. DOI: 10.1182/bloodadvances.2022008327.

References

Abeni D, Frontani M, Sampogna F, Sera F, Bolli S, Corona R . Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol. 2005; 153(2):324-30. DOI: 10.1111/j.1365-2133.2005.06755.x. View

Novelli M, Fava P, Sarda C, Ponti R, Osella-Abate S, Savoia P . Blood flow cytometry in Sézary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up. Am J Clin Pathol. 2014; 143(1):57-69. DOI: 10.1309/AJCP1NA3YCHCDEIG. View

Geskin L, Akilov O, Lin Y, Lokshin A . Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol. 2014; 23(8):598-600. PMC: 4125529. DOI: 10.1111/exd.12455. View

Ralfkiaer U, Hagedorn P, Bangsgaard N, Lovendorf M, Ahler C, Svensson L . Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011; 118(22):5891-900. PMC: 3342856. DOI: 10.1182/blood-2011-06-358382. View

Vermeer M, van Doorn R, Dijkman R, Mao X, Whittaker S, van Voorst Vader P . Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res. 2008; 68(8):2689-98. DOI: 10.1158/0008-5472.CAN-07-6398. View

Santucci M, Biggeri A, Feller A, Burg G . Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-cell lymphoma: an EORTC Cutaneous Lymphoma Project Group Study. European Organization for Research and Treatment of Cancer. Arch Dermatol. 2000; 136(4):497-502. DOI: 10.1001/archderm.136.4.497. View

Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R . Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol. 1999; 40(6 Pt 1):914-24. DOI: 10.1016/s0190-9622(99)70079-4. View

Marti R, Pujol R, Servitje O, Palou J, Romagosa V, Bordes R . Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma. 2003; 44(1):59-69. DOI: 10.1080/1042819021000054652. View

Bahler D, Hartung L, Hill S, Bowen G, Vonderheid E . CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry. Cytometry B Clin Cytom. 2007; 74(3):156-62. DOI: 10.1002/cyto.b.20395. View

10.

Cetinozman F, Jansen P, Vermeer M, Willemze R . Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol. 2012; 148(12):1379-85. DOI: 10.1001/archdermatol.2012.2089. View

11.

Vidulich K, Talpur R, Bassett R, Duvic M . Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol. 2009; 48(3):243-52. DOI: 10.1111/j.1365-4632.2009.03771.x. View

12.

Salgado R, Gallardo F, Servitje O, Estrach T, Garcia-Muret M, Romagosa V . Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas. Cancer Genet. 2011; 204(7):405-9. DOI: 10.1016/j.cancergen.2011.05.004. View

13.

Scala E, Russo G, Cadoni S, Narducci M, Girardelli C, De Pita O . Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion. J Invest Dermatol. 1999; 113(4):622-7. DOI: 10.1046/j.1523-1747.1999.00718.x. View

14.

Chapman C, Healey G, Murray A, Boyle P, Robertson C, Peek L . EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012; 33(5):1319-26. PMC: 3460172. DOI: 10.1007/s13277-012-0379-2. View

15.

van Doorn R, Dijkman R, Vermeer M, Out-Luiting J, van der Raaij-Helmer E, Willemze R . Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis. Cancer Res. 2004; 64(16):5578-86. DOI: 10.1158/0008-5472.CAN-04-1253. View

16.

Jiang L, Yuan C, Hubacheck J, Janik J, Wilson W, Morris J . Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009; 145(2):173-9. PMC: 3487105. DOI: 10.1111/j.1365-2141.2009.07606.x. View

17.

Narducci M, Arcelli D, Picchio M, Lazzeri C, Pagani E, Sampogna F . MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome. Cell Death Dis. 2011; 2:e151. PMC: 3122063. DOI: 10.1038/cddis.2011.32. View

18.

Cedeno-Laurent F, Singer E, Wysocka M, Benoit B, Vittorio C, Kim E . Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015; 158(1):1-7. PMC: 4420663. DOI: 10.1016/j.clim.2015.02.014. View

19.

Malek M, Glen J, Rebala K, Kowalczyk A, Sobjanek M, Nowicki R . Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. Acta Derm Venereol. 2014; 95(3):283-8. DOI: 10.2340/00015555-1958. View

20.

Woollard W, Pullabhatla V, Lorenc A, Patel V, Butler R, Bayega A . Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome. Blood. 2016; 127(26):3387-97. DOI: 10.1182/blood-2016-02-699843. View